Trump said he will raise tariffs on $250 billion in Chinese goods to 30%, and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
Bank of England Governor Mark Carney says trade war has a confidence effect on business around the worldMarketsread more
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday.Politicsread more
The wild ride continued on Thursday for shares of Canadian pot company Tilray.
The stock captivating trading desks across the country rose as much as 14 percent at one point, only to give up that gain and go negative about an hour into trading.
It closed down 17.6 percent. The stock swung in a wide range in the overnight session, down by 19 percent at one point and up by more than 11 percent.
Tilray shares overnight
Tilray shares were on fire the previous two days, but with plenty of bumps along the way. In that time period, the stock has shot up 56 percent. The stock was driven 38.1 percent higher on Wednesday after CEO Brendan Kennedy told CNBC's Jim Cramer that global pharmaceuticals must think about partnering cannabis producers as a "hedge" against the space. On Tuesday, the stock surged 28.9 percent after Tilray announced the Drug Enforcement Administration approved it to import marijuana to the U.S. for medical research.
But trading in the stock was halted five times on Wednesday as it failed to hold a more than 90 percent gain. Tilray shares even turned lower at one point before closing up 38.1 percent.
These wild price swings could also be a byproduct of the small number shares of the stock that are available for trading as well as the large number of those shares sold short. Tilray currently has 21.7 million floating shares and 19.5 percent of those are being used to bet against the company, according to FactSet data.
Still, the stock has had a meteoric rise since going public in July. Tilray — which priced its initial public offering at $17 per share — is up more than 1,100 percent since its IPO and nearly 500 percent over the past month.